SCHEMBL4174786

SCHEMBL4174786

Cc1ccc(S(=O)(=O)NC(CC(=O)O)C(=O)NC(C)CO)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
ADAMTS4 O75173 1/20 0.47
ALDH1A1 P00352 3/20 0.47
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
TSHR P16473 1/20 0.47
MMP13 P45452 4/20 0.46
MMP2 P08253 2/20 0.46
MMP3 P08254 2/20 0.46
MMP9 P14780 2/20 0.46
MMP1 P03956 1/20 0.46
MMP7 P09237 1/20 0.46
PSMB8 P28062 4/20 0.46
PSMB5 P28074 2/20 0.45
GAA P10253 1/20 0.44
PLAU P00749 1/20 0.44
HPN P05981 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174029 0.84 ALDH1A1 (0.44) ALDH1A1CA12CA2CA9TSHR
SCHEMBL4174025 0.84 ALDH1A1 (0.44) ALDH1A1CA12CA2CA9TSHR
SCHEMBL698842 0.81 TDP1 (0.63) TDP1ADAMTS4ALDH1A1CA12CA2
SCHEMBL4339865 0.81 TDP1 (0.63) TDP1ADAMTS4ALDH1A1CA12CA2
SCHEMBL698843 0.81 TDP1 (0.63) TDP1ADAMTS4ALDH1A1CA12CA2
SCHEMBL5572742 0.79 MMP9 (0.62) TDP1ADAMTS4ALDH1A1MMP13MMP2
SCHEMBL16519484 0.78 CA2 (0.68) ALDH1A1CA12CA2CA9TSHR
SCHEMBL16519485 0.78 CA2 (0.68) ALDH1A1CA12CA2CA9TSHR
SCHEMBL4752500 0.78 CA2 (0.68) ALDH1A1CA12CA2CA9TSHR
SCHEMBL4697964 0.77 TDP1 (0.49) TDP1ADAMTS4ALDH1A1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227601-A1 Bradykinin 1 Receptor Antagonists AMGEN INC. (US) 2009-09-10 US disclosed
EP-1963285-A1 BRADYKININ 1 RECEPTOR ANTAGONISTS Amgen Inc. (US) 2008-09-03 EP disclosed
WO-2007067629-A1 BRADYKININ 1 RECEPTOR ANTAGONISTS AMGEN INC. (US) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227601-A1 Bradykinin 1 Receptor Antagonists BDKRB1, BDKRB2, VIPR1 TDP1 2997/4885ADAMTS4 1142/4885ALDH1A1 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.